✦ LIBER ✦

Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer

✍ Scribed by Se Hoon Park; Jeeyun Lee; Se Hoon Lee; Joon Oh Park; Kihyun Kim; Won Seog Kim; Chul Won Jung; Young Suk Park; Won Ki Kang; Keunchil Park; Seonwoo Kim; Soo Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee

Publisher: Springer
Year: 2005
Tongue: English
Weight: 199 KB
Volume: 57
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-005-0027-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progression-free survival in first-line

Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer

✍ Kenji Hashimoto; Atsuo Takashima; Kengo Nagashima; Shun-suke Okazaki; Takako Egu 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 326 KB

Prediction of clinical outcome of fluoro

Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway

✍ Wataru Ichikawa 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 376 KB

Impacts of fluorouracil-metabolizing enz

Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer

✍ Wasaburo Koizumi; Satoshi Tanabe; Mizutomo Azuma; Kenji Ishido; Ken Nishimura; T 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 267 KB

## Abstract A phase III trial of S‐1 plus cisplatin (SP) __versus__ S‐1 alone, for first‐line treatment of advanced gastric cancer (SPIRITS trial), has shown that overall survival was better in patients treated with SP than with S‐1 alone. In the present retrospective biomarker study, we aimed to d

Second-line chemotherapy with fluorourac

Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy : A multicenter AGEO study

✍ Aziz Zaanan; Mélanie Gauthier; David Malka; Christophe Locher; Jean-Marc Gornet; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 1 views

## Abstract ## BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced SBA, but data regarding second‐line chemotherapy are lacking. The aim of this study was to evaluate the efficacy and tolerabil